Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

HVHarjot VohraEAEshetu G. AtenafuJKJohn Kuruvilla

Discussion

Loading...

Member takes

Overview

Observational analysis reveals high rate of cytopenias post CAR T-cell therapy in large B-cell lymphoma patients, suggesting need for monitoring adverse outcomes.

Key Points

  • Late cytopenias were observed in 35% of patients between day 30 and 100 post CAR T-cell therapy, indicating persistent toxicity.
  • Anemia affected 94.6% of patients at one month, while neutropenia and thrombocytopenia occurred in 62.8% and 82%, respectively.
  • This retrospective analysis involved patients with relapsed refractory large B-cell lymphoma undergoing CAR T-cell therapy, providing insights into cytopenias' trajectory.
  • High CAR-HT score predicted any grade immune effector cell-associated hematotoxicity at three months, highlighting its clinical utility for monitoring.

Cite This Study

Vohra et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e27ahttps://doi.org/10.1182/blood-2025-5505
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cytopenias and infectious complications following CD19-directed CAR-T cell therapy in patients with B-ALL: A single-center retrospective analysis2025
  2. 2The prognostic value of CAR-hematox in predicting toxic events in patients with relapsed refractory B cell lymphoma receiving 7x19 CAR-T treatment2025
  3. 3CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)2025
  4. 4Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival2025
  5. 5Poor neutrophil recovery following CD19-targeted CAR-T cell therapy predicts inferior outcomes in adult patients with B-cell lymphoma2025